Studies by Petrelli et al. (2020) and Mao et al. (2023) identify mutations in genes such as USH2A, ZFHX4, and PLCO as being highly correlated with enhanced tumor immunogenicity and improved outcomes with ICIs [19,21]. This evidence concerns the gene USH2A and neoplasm.